CAI
Caris Life Sciences, Inc.
$30.71
+0.49% 2026-10-19
Healthcare
CAISPY
1W
+3.4%
1M
+2.4%
3M
+97.4%
6M
+44.6%
YTD
+13.8%
1Y
-2.5%
Grades vs sector
Momentumno data–
Momentum
no data
Percentile within its GICS sector across the S&P 1500.
Growthno data–
Growth
no data
Percentile within its GICS sector across the S&P 1500.
Valueno data–
Value
no data
Percentile within its GICS sector across the S&P 1500.
Profitabilityno data–
Profitability
no data
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$8.7B
P/E (trailing)18.2
P/E (forward)82.6
52-week range14.19 – 33.13
Revenue growth (YoY, latest qtr)+45.4%
Dividend yield0.00%
Analyst consensusBuy (13)
Mean price target$32.23 (+5%)
Valuation & fundamentals
Bottom line
Leans undervalued
Model read-out from the numbers below, not advice. Score +2 (DCF counts double).
▲DCF (base case)above the price by 17%
•Piotroski F-score5/9
▲Altman Z7.3 (safe)
▲Net debt / EBITDA-3.0x
•Analyst target+5% (13 analysts)
Discounted cash flow
Bear
$17
-45%
growth 18% · disc. 10.2% · term. 2.0%
Base
$36
+17%
growth 30% · disc. 9.2% · term. 2.5%
Bull
$67
+118%
growth 38% · disc. 8.2% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 20% a year for 10 years.
Implied
+20%/yr
FCF, last 3 yrs
n/a
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
n/a
Revenue, last 5 yrs
n/a
Same inputs as the DCF above: trailing free cash flow 0.1B, 9.2% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $0.37 vs trailing $1.69 (-78% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
–
Operating margin
15.5%
FCF margin
14.6%
Net margin
10.6%
Return on equity
17.8%
Return on invested capital
244.1%
Net debt / EBITDA
-3.0×
Current ratio
5.5×
Interest cover
3.3×
Cash conversion (OCF/NI)
1.6×
Piotroski F-score 5/9 · last two fiscal years
✗ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✗ Asset turnover improved
Altman Z-score 7.3 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$32
+5%
Analysts
13
Buy
Range
$24–$38
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $812.0M | $-68.1M | $66.9M |
| 2024 | $412.3M | $-281.9M | $-253.6M |
| 2023 | $306.1M | $-341.4M | $-298.4M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
Next report: 2026-11-04 · during market · EPS est 0.02
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-02-26 | 0.10 | 0.28 | +168.7% |
| 2025-11-05 | -0.14 | 0.08 | +158.8% |
| 2025-08-12 | -0.22 | -1.11 | -411.2% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $263.7M | +45.4% |
| 2026-03-31 | $216.2M | – |
| 2025-12-31 | $292.9M | – |
| 2025-09-30 | $216.8M | – |
| 2025-06-30 | $181.4M | – |
Analyst actions
Canaccord Genuity
PT $30
2026-10-19 · main
Hold → HoldPT $30
JP Morgan
PT $35
2026-10-14 · main
Overweight → OverweightPT $35
TD Cowen
PT $36
2026-10-13 · main
Buy → BuyPT $36
UBS
PT $28
2026-09-09 · init
→ NeutralPT $28
Evercore ISI Group
PT $26
2026-08-06 · main
Outperform → OutperformPT $26
BTIG
PT $33
2026-08-06 · main
Buy → BuyPT $33
Insider trades
Denton John Russel
$238.6K
See Remarks · 2026-09-22
SELL$238.6K
Brille Brian J
$12.1M
Director, See Remarks · 2026-09-17
SELL$12.1M
Spetzler David Baxley
$3.0M
President · 2026-09-04
SELL$3.0M
Spetzler David Baxley
$9.7M
President · 2026-09-03
SELL$9.7M
Spetzler David Baxley
$2.1M
President · 2026-09-03
SELL$2.1M
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
News
Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection
PR Newswire · Oct 19
Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
PR Newswire · Oct 15
Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026
PR Newswire · Oct 14
CAI Expands Delaware Partnership to Meet New Benefit Accuracy Requirements
GlobeNewswire · Oct 13
BofA Securities Adjusts Caris Life Sciences Price Target to $35 From $23
MT Newswires · Oct 09
IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
Investor's Business Daily · Oct 02
Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure
PR Newswire · Sep 29
SMT Energy and CAI agree to $268m equity deal
Energy Monitor · Sep 23
Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look
Investor's Business Daily · Sep 22
Stats refreshed 2026-10-19 19:02:27 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.